Want to see HK:2575 full AI Analyst Report?
Top Page
Xuanzhu Biopharmaceutical Co., Ltd. Class H
(2575)
Select Model
Select Model
Rating:48Neutral
Price Target:
HK$9.00
▼(-30.50% Downside)
Action:Reiterated
Date:09/18/26
The score is held back primarily by ongoing losses and continued negative operating/free cash flow despite strong revenue growth and a low-debt balance sheet. Technicals are also weak, with the price below key moving averages and negative MACD, while valuation is constrained by a negative P/E and no dividend yield data.
Positive Factors
Revenue Scaling
Rapid revenue expansion indicates that the company is achieving meaningful commercial traction and broadening its business base. If this growth persists, greater scale can improve operating leverage, support continued investment, and create a stronger foundation for eventual profitability.
Negative Factors
Persistent Losses
Persistent operating and net losses show that the current business model has not yet reached sustainable profitability despite strong revenue growth. Continued losses can constrain internal funding, require ongoing execution improvements, and leave earnings performance vulnerable if growth or margins weaken.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Scaling
Rapid revenue expansion indicates that the company is achieving meaningful commercial traction and broadening its business base. If this growth persists, greater scale can improve operating leverage, support continued investment, and create a stronger foundation for eventual profitability.
Read all positive factors
Xuanzhu Biopharmaceutical Co., Ltd. Class H (2575) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$4.79B
Dividend YieldN/A
Average Volume (3M)2.03M
Price to Earnings (P/E)―
Beta (1Y)2.43
Revenue Growth237.19%
EPS Growth61.28%
CountryHK
Employees342
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding517,947,800
10 Day Avg. Volume3,716,427
30 Day Avg. Volume2,027,207
Financial Highlights & Ratios
PEG Ratio2.47
Price to Book (P/B)23.93
Price to Sales (P/S)650.34
P/FCF Ratio-163.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Xuanzhu Biopharmaceutical Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Xuanzhu Biopharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the research, production, and commercialization of both small-molecule chemical compounds and large-molecule biopharmaceuticals. The company's primary drug candidates include...
Xuanzhu Biopharmaceutical Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
78
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.74M | 56.15M | 32.63M | 32.04K | 0.00 |
| Gross Profit | -5.08M | 21.80M | -12.60M | -35.52M | -30.16M |
| EBITDA | -63.00M | -220.55M | -566.36M | -295.28M | -563.77M |
| Net Income | -69.99M | -266.26M | -603.29M | -332.12M | -595.70M |
Balance Sheet | |||||
| Total Assets | 1.21B | 1.83B | 1.27B | 1.45B | 1.63B |
| Cash, Cash Equivalents and Short-Term Investments | 216.62M | 765.43M | 294.13M | 495.15M | 792.98M |
| Total Debt | 1.37M | 720.64K | 1.57M | 18.79M | 32.82M |
| Total Liabilities | 257.79M | 300.83M | 255.31M | 232.05M | 130.75M |
| Stockholders Equity | 956.22M | 1.53B | 1.02B | 1.22B | 1.50B |
Cash Flow | |||||
| Free Cash Flow | -70.02M | -223.60M | -105.22M | -130.05M | -501.15M |
| Operating Cash Flow | -70.01M | -222.97M | -104.67M | -128.13M | -449.15M |
| Investing Cash Flow | -49.88M | 121.20M | 143.04M | 49.43M | -579.14M |
| Financing Cash Flow | -1.69M | 675.14M | -13.47M | -10.94M | -14.14M |
Xuanzhu Biopharmaceutical Co., Ltd. Class H Technical Analysis
Negative
12.95
Price Trends
11.04
Negative
14.09
Negative
34.93
Negative
Market Momentum
-0.74
Negative
41.28
Neutral
31.18
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2575, the sentiment is Negative. The current price of 12.95 is above the 20-day moving average (MA) of 9.62, above the 50-day MA of 11.04, and below the 200-day MA of 34.93, indicating a bearish trend. The MACD of -0.74 indicates Negative momentum. The RSI at 41.28 is Neutral, neither overbought nor oversold. The STOCH value of 31.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2575.
Xuanzhu Biopharmaceutical Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$208.00B | 26.58 | 18.26% | 1.26% | 24.97% | 43.23% | |
60 Neutral | HK$18.79B | 148.43 | 1.43% | ― | -8.55% | -96.20% | |
56 Neutral | HK$14.49B | 66.98 | 1.67% | 4.42% | 3.10% | -46.64% | |
53 Neutral | HK$12.62B | 347.02 | 0.82% | 1.31% | 38.42% | ― | |
52 Neutral | HK$2.24B | -19.26 | -10.61% | ― | 83.49% | -110.21% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$4.79B | -18.15 | -20.93% | ― | 237.19% | 61.28% |
* Healthcare Sector Average
HK:2575
Xuanzhu Biopharmaceutical Co., Ltd. Class H
9.14
-19.86
-68.48%
HK:0013
HUTCHMED (China)
22.46
-3.98
-15.05%
HK:2552
Hua Medicine
2.49
-1.77
-41.53%
HK:9989
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
3.88
-1.54
-28.39%
HK:3692
Hansoh Pharmaceutical Group Company Limited
35.56
0.43
1.21%
HK:6185
CanSino Biologics, Inc. Class H
28.18
-22.62
-44.53%
Xuanzhu Biopharmaceutical Co., Ltd. Class H Corporate Events
Xuanzhu Biopharmaceutical Flags Share Price Surge Amid Early-Stage Acquisition Talks
Sep 17, 2026
Xuanzhu Biopharmaceutical Co., Ltd. reported unusual price movements in its Hong Kong-listed H shares, noting a sharp increase in the stock on the day of the announcement. The board stated that, after reasonable inquiries, it was not aware of any ...
Xuanzhu Biopharma INEDs Report No Conflicts With Controlling Shareholders in 2025 Review
Sep 16, 2026
Xuanzhu Biopharmaceutical Co., Ltd., a Hong Kong-listed Chinese biopharma group, has established governance measures to manage potential conflicts of interest with its controlling shareholders, relying on independent non-executive directors to rev...
Xuanzhu Biopharma Strikes Thailand Commercial Deal for Breast Cancer Drug Bireociclib
Sep 3, 2026
Xuanzhu Biopharmaceutical has signed a tri-party commercial agreement with Thailand’s Innobic (Asia) and Hong Kong-based ZaoAn International, granting them exclusive rights to commercialise its breast cancer drug Bireociclib in Thailand thro...
Xuanzhu Biopharmaceutical Narrows Interim Loss as Revenue Surges on New Products
Aug 26, 2026
Xuanzhu Biopharmaceutical reported interim revenue of RMB69.4 million for the six months ended June 30, 2026, a 288.1% jump from a year earlier as sales volumes rose on the back of new product launches and broader reimbursement coverage. Operating...
Xuanzhu Biopharmaceutical Sets Board Meeting to Approve 2026 Interim Results
Aug 13, 2026
Xuanzhu Biopharmaceutical has scheduled a board meeting for August 26, 2026 to review and approve its interim results for the six months ended June 30, 2026, and to authorize their publication. The board will also consider whether to recommend the...
Xuanzhu Biopharm ordered to pay RMB9.33 million in arbitration over generic drug deal
Jul 19, 2026
Xuanzhu Biopharmaceutical Co., Ltd. has disclosed that an arbitration tribunal of the China International Economic and Trade Arbitration Commission has issued a final award against the company arising from a technology transfer contract for a gene...
Xuanzhu’s Anaprazole Wins NMPA Review Nod for Reflux Esophagitis
Jun 30, 2026
Xuanzhu Biopharmaceutical has reported that China’s National Medical Products Administration has formally accepted its New Drug Application for a new indication of Anaprazole Sodium Enteric-coated Tablets in the treatment of adult reflux eso...
Xuanzhu Biopharma Advances Anaprazole into Phase III Trial for H. pylori Eradication
Jun 21, 2026
Xuanzhu Biopharmaceutical has enrolled the first patient in a Phase III, multi-centre, randomized, double-blind clinical trial evaluating its innovative proton pump inhibitor Anaprazole Sodium as part of a bismuth-containing quadruple therapy for ...
Xuanzhu Biopharmaceutical Shareholders Approve AGM Resolutions and Governance Overhaul
Jun 18, 2026
Xuanzhu Biopharmaceutical Co., Ltd. reported that all resolutions at its 2025 annual general meeting in Beijing were approved by shareholders via poll, including the 2025 board report, audited financial statements, annual report, profit distributi...
Xuanzhu Biopharmaceutical Adds Employee Representative to Board as Executive Director Resigns
Jun 18, 2026
Xuanzhu Biopharmaceutical has reshaped its board composition by appointing an employee representative director to replace an executive director position, a move approved at its June 18, 2026 annual general meeting. The change takes effect immediat...
Xuanzhu Biopharmaceutical updates board and committee roles
Jun 18, 2026
Xuanzhu Biopharmaceutical has published an updated list of its board of directors, detailing the roles of executive, non-executive, independent and employee representative members, including Chairperson and General Manager Xu Yanjun. The company a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.